Pfizer Inc. (NYSE:PFE) Holdings Decreased by Bank Hapoalim BM

Bank Hapoalim BM trimmed its position in Pfizer Inc. (NYSE:PFE) by 8.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,118 shares of the biopharmaceutical company’s stock after selling 11,100 shares during the quarter. Bank Hapoalim BM’s holdings in Pfizer were worth $3,160,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in PFE. Czech National Bank increased its holdings in shares of Pfizer by 6.9% in the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after acquiring an additional 74,737 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after acquiring an additional 13,097 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Pfizer by 33.8% in the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock valued at $3,285,000 after acquiring an additional 28,658 shares during the last quarter. Ignite Planners LLC increased its holdings in shares of Pfizer by 1.5% in the 3rd quarter. Ignite Planners LLC now owns 34,144 shares of the biopharmaceutical company’s stock valued at $988,000 after acquiring an additional 518 shares during the last quarter. Finally, Chapin Davis Inc. grew its stake in Pfizer by 2.8% during the 3rd quarter. Chapin Davis Inc. now owns 59,981 shares of the biopharmaceutical company’s stock worth $1,736,000 after buying an additional 1,627 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 1.2 %

Shares of Pfizer stock opened at $25.88 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $146.64 billion, a price-to-earnings ratio of 34.97, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The business has a fifty day simple moving average of $26.27 and a 200-day simple moving average of $27.82. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. Pfizer’s dividend payout ratio is 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.